Meeting
2018 ASCO Annual Meeting
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
Authors
Pasi A. Janne
Dana-Farber Cancer Institute, Boston, MA
Pasi A. Janne , Helena Alexandra Yu , Melissa Lynne Johnson , Michele Vigliotti , Nicole Shipitofsky , Ferdinand Morales Guevara , Shuquan Chen , Channing Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03260491
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9110)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9110
Abstract #
TPS9110
Poster Bd #
430a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
First Author: Dali Edwards
Poster
2023 ASCO Quality Care Symposium
Stomatitis in patients receiving EGFR-targeted therapy for non-small cell lung cancer: A population-based cohort study across the United States.
First Author: Chuan Lu
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.
First Author: Yuankai Shi